Hosted on MSN6h
Glenmark Expands Ophthalmic Portfolio in the US with Latanoprost Launch
Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening ...
Active Biotech AB: Active Biotech Year End Report 2024
EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant ...
ophthalmologyadvisor20h
Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy
The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic ...